EVM
PCRX icon

Eaton Vance Management’s Pacira BioSciences PCRX Stock Holding History

Eaton Vance Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,073
Closed -$65K – 2454
2021
Q4 		$65K Buy
1,073
+570
+113% +$31.4K ﹤0.01% 2001
2021
Q3 		$0 Sell
503
-263
-34% -$15.2K ﹤0.01% 2505
2021
Q2 		$47K Buy
766
+388
+103% +$24.6K ﹤0.01% 2177
2021
Q1 		$26K Buy
+378
New +$27K ﹤0.01% 1983
2018
Q2 		– Sell
-271,106
Closed -$8.44M – 1186
2018
Q1 		$8.44M Buy
271,106
+65,970
+32% +$2.35M 0.01% 547
2017
Q4 		$9.36M Hold
205,136
– – 0.02% 397
2017
Q3 		$7.7M Sell
205,136
-204,065
-50% -$8.21M 0.02% 414
2017
Q2 		$19.5M Buy
+409,201
New +$19M 0.05% 262

Other funds holding PCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return